MBD3 and leukemia: These efforts and additional validation experiments revealed PSIP1, CREBBP, and kinase FLT3 representing known vulnerabilities in KMT2A-r, as well as ARID4B, MBD3, and BMPR2 as potential candidates to be considered as novel therapeutic targets in this aggressive type of leukemia.